The TROP2 antibody drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) improved survival, compared with platinum-based chemotherapy, in patients with EGFR-mutated non-small cell lung cancer (NSCLC) ...
Despite no difference in event-free survival found between short and long preoperative chemo, long preoperative significantly increased CA19-9 response rate, N0 resection rate, number of the ...
IMFINZI® (durvalumab)-basedregimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial More than two thirds of patients treated with ...
Positive results from the TROPION-Breast02 phase 3 trial showed DATROWAY ® (datopotamab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement for the dual primary ...
Nivolumab plus ipilimumab significantly improves OS and PFS in NSCLC compared to chemotherapy, with a 30% reduction in death risk and no significant heterogeneity observed. Amivantamab plus lazertinib ...
Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025 ...
Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback